Currently, surgery-based comprehensive lung cancer treatment has been recognized, and patients who obtain surgical treatment have substantially better survival time and quality of survival than those who do not. It is widely reported in the literature that the survival time after lung cancer surgery is much higher than that after receiving only radiotherapy or chemotherapy. For lung cancer patients treated with surgery, whether the lung cancer is at an early stage, the degree of malignancy, whether the surgical method is correctly selected, whether the resection is standardized and complete, whether there are lymph node metastases, whether the lymph node dissection is standardized and complete, whether the postoperative adjuvant therapy is appropriate, and whether the postoperative review is regular, all have an impact on the surgical outcome and survival time. The postoperative survival of lung cancer mainly depends on whether it is treated early or not. The earlier the surgery, the better the result and the longer the survival time, for example, the 5-year survival rate of IA can be over 70%. Second, how malignant the degree of malignancy is also one of the key factors to determine how long lung cancer can live. According to pathological examination, tumors with high cell differentiation have low malignancy and longer survival time; while tumors with low differentiation have high malignancy and survival time will be affected. Tumors with low differentiation often need adjuvant radiotherapy and chemotherapy after surgery to consolidate the efficacy of surgery. Therefore, the ideal standardized lung cancer surgery requires complete removal of tumor and lymph nodes, while preserving as much lung function as possible. A thorough resection of lesions can ensure that tumor tissues are completely removed from the body, laying a solid foundation for radical treatment of lung cancer, while largely reducing the risk of recurrence and metastasis. 2. Standardized and systematic lymph node dissection is equally important as complete removal of tumor lesions, which are key factors affecting survival time after surgery. This point should be given special attention! Preserving more healthy lung tissues after lung cancer surgery is also one of the key factors affecting the prognosis of lung cancer. Preserving as much healthy lung tissues as possible during surgery can reduce the damage to the body on one hand, and on the other hand, more abundant lung function can significantly help the quality of life and mobility after surgery. To achieve this it is necessary to choose the correct surgical fraction and at the same time to have a high level of surgical skill. For example, choosing lobe sleeve resection to avoid total pneumonectomy, which means that the part invaded by the tumor is fully removed, and then the healthy lung is preserved and re-transplanted back to function again. With the continuous development of medicine, thoracoscopic minimally invasive radical lung cancer surgery has become the development direction of lung cancer surgery. As proved by numerous surgeries at home and abroad and by us, minimally invasive surgery not only achieves 100% of the effect of open-heart surgery, but even more thorough and clean surgical clearance because of the magnification function of thoracoscope. Moreover, minimally invasive surgery is less traumatic, less painful, faster recovery, longer survival time and higher quality of survival after surgery. 5, the correct comprehensive assessment before surgery and the appropriate neoadjuvant therapy preoperative full assessment of the patient’s condition, can have a more full and comprehensive understanding of the patient’s situation, the decision on the mode of surgery and the choice of postoperative adjuvant therapy can be more fully assessed. Neoadjuvant therapy can have the opportunity to regain surgical opportunities for some patients who have lost the chance of surgery in the preoperative evaluation. Fourth, correct and timely adjuvant therapy after surgery is the most important and crucial step in lung cancer treatment, but post-surgery consolidation therapy is also important. Correct radiotherapy and chemotherapy after surgery can effectively consolidate the effect of surgery and help to win longer survival time. Targeted therapy is an advanced and effective adjuvant therapy in lung cancer treatment in recent years. Compared with traditional radiotherapy and chemotherapy, targeted therapy is more effective and has fewer side effects, which is the development direction of adjuvant lung cancer treatment in the future. The key to targeted therapy is gene therapy, and the key lies in the accuracy of gene testing. Using surgical resection specimens for testing is recognized as the most accurate and reliable testing results, which can bring more comprehensive guidance to targeted therapy. V. Individual differences in malignant tumors are very obvious. The same pathological type, the same degree of malignancy, the same stage of lung cancer, and the same surgical method may have different effects on survival time because of the differences of patients. Individualized treatment for lung cancer is aimed at eliminating the influence of individual differences on lung cancer prognosis and formulating individualized treatment plans for different patients to fully ensure the efficacy of lung cancer treatment. In the process of lung cancer treatment, we have formulated adequate and standardized treatment measures, including: 1. Surgery according to the best internationally recognized standards, surgical standardization and complete resection. complete resection through rapid pathological examination. After the operation, all the excised tissues will be sorted into different categories and sent for pathological examination, which will eventually lead to accurate pathological diagnosis and pathological staging and provide the most important basis for guiding whether and how to carry out adjuvant treatment after the operation. 2.Maximum preservation of healthy lung tissues, high quality of life after surgery At the same time, we focus on improving the quality of life of patients after surgery. 3. Most patients are treated with minimally invasive surgery Minimally invasive surgery has a very positive impact on postoperative recovery and postoperative survival time of lung cancer patients. We take the lead in carrying out minimally invasive thoracoscopic surgery in China, especially in Hubei Province, and various minimally invasive surgeries have become our surgical strengths and features, and we have accumulated rich experience and are at the leading level nationwide, with satisfactory surgical results. Minimally invasive surgical treatment is less traumatic, less painful, quicker recovery, better surgical results and shorter hospitalization time. 4.The long-term effect of post-surgical adjuvant therapy is not only affected by the resection of local lesions, but also involves the recurrence of lung cancer and distant metastasis. Therefore, we will correctly guide and arrange patients for post-surgical adjuvant therapy according to their post-surgical pathological types, lymph node metastasis and other aspects. 5.Long-term follow-up service after discharge and long-term rehabilitation and treatment guidance After patients are discharged from the hospital, we will provide long-term post-operative guidance to patients through telephone and QQ on a regular basis to keep abreast of the changes of their conditions and provide review and next treatment guidance. Patients will be provided with advanced, correct, standardized and systematic treatment and services for a long time. From our follow-up results, the survival rate of our surgical treatment of lung cancer is much higher than the average reported at home and abroad, for example, the 3-year survival rate reaches 65.6%, which is much higher than the 40% reported at home and abroad . In general, lung cancer is a malignant tumor with high malignancy, morbidity and mortality. However, it must be clearly understood that malignant tumor is a disease with significant individual differences, and the evidence of survival time and quality of survival we have obtained so far can only be used as a broad reference, and how long lung cancer patients can live is still a complex issue. The question is still a complex one. Early detection, early treatment, choosing regular medical institutions and obtaining individualized treatment plans can extend the life span of lung cancer patients as much as possible.